News Release

Cellular signatures of kidney tumours discovered

Peer-Reviewed Publication

Wellcome Trust Sanger Institute

The origins of seven types of kidney cancer, including several rare subtypes, have been identified by researchers at the Wellcome Sanger Institute, Great Ormond Street Hospital (GOSH), the Princess Máxima Center for Pediatric Oncology and Oncode Institute. The findings confirm that these cancers have their origin in specific forms of developmental cells present in the maturing fetus.

The study, published today (23 June) in Nature Communications, used computational methods to analyse existing datasets and pinpoint the 'cellular signals' given off by different cancers as they emerge. This method holds promise as a tool for diagnosing patients with rare cancers - in the study, one patient's cryptic kidney cancer was identified as a Wilms-like tumour by looking at its cellular signals.

All cancers are derived from normal cells that have started to multiply uncontrollably. By comparing patterns of gene expression in cancer and normal cells, it is possible to learn about aspects of each tumour's origin and behaviour. This type of analysis has been made possible by the advent of single-cell mRNA sequencing, a high-resolution technology that can identify different cell types present in a tissue according to the genes expressed by individual cells.

Previous studies have used these techniques to compare normal and diseased tissue in some of the most common kidney cancers, but to conduct single-cell sequencing on many hundreds of tumours would not be achievable.

In this study, researchers at the Wellcome Sanger Institute and their collaborators turned to computational techniques to mine Human Cell Atlas (HCA) reference data* and databases of tumour gene expression. They assessed mRNA signals in 1,300 childhood and adult renal tumours, spanning seven different tumour types, in order to investigate the origins of these cancers**.

The results confirmed that these childhood cancers are developmental in origin, occurring after errors in a particular developmental cell type's journey to maturity. In contrast, adult kidney cancers emerged from mature cell types and do not revert to a developmental pattern of gene expression in the vast majority of cases.

Each cancer type was also found to exhibit unique 'cellular signals', or patterns of gene expression, that could be used to classify them in future.

Dr Matthew Young, first author of the study from the Wellcome Sanger Institute, said: "It has long been assumed that childhood tumours have 'fetal' origins. Now we can replace that loose definition with a precise, quantitative measurement of the cellular signals that different tumour types exhibit. Our analysis also refutes the theory that adult tumours revert to a developmental state, unless they are a highly lethal subtype of adult kidney cancer."

The study sheds light on the behaviour and origins of some kidney tumour subtypes whose rarity would have made it difficult to examine otherwise. These were congenital mesoblastic nephroma, clear cell sarcoma of the kidney, malignant rhabdoid tumour of the kidney, and chromophobe renal cell carcinoma.

The method pioneered in the study also helped to classify one patient's tumour, which clinicians had been unable to diagnose fully.

Dr Karin Straathof, a senior author of the study from Great Ormond Street Hospital, said: "Sometimes it is not possible to fully diagnose childhood kidney cancers via the usual methods, which can impact our ability to adopt the best course of treatment. One of the samples used in this study was from a child with one of these undiagnosed tumours. But by analysing the genes expressed by the tumour cells, we were able to recognise it as Wilms' tumour. My hope is that this approach can be used in such cases in future."

In recent studies, researchers have identified the origins of individual childhood cancers, such as neuroblastoma, using mRNA single-cell sequencing on small numbers of tumours. Here, computational analysis of existing data has been used to determine the origin of a larger groups of childhood cancers.

Dr Sam Behjati, a senior author of the study from the Wellcome Sanger Institute, said: "Not only does this computational approach using existing datasets validate previous results on the origins of childhood kidney cancers, it provides a new way of expanding this research to much larger numbers of tumours and rare cancer types. I believe that the success of this approach could act as a blueprint for investigating the behaviour and origins of the entire spectrum of human cancer."


Contact details:

Dr Matthew Midgley
Press Office
Wellcome Sanger Institute
Cambridge, CB10 1SA
Phone: 01223 494856

Notes to Editors:

*Single-cell RNA sequencing (scRNAseq), used to assess which genes are active in individual cells, can be used on millions of cells at once and generates vast amounts of data. The Human Cell Atlas project uses such techniques to uncover and characterise all of the cell types present in an organism or population.

** Bulk transcriptomes are an aggregate of gene expression for both tumour and normal cells. The types of cancer analysed in the study were:

  • Congenital mesoblastic nephroma (CMN)
  • Nephroblastoma (also known as Wilms tumour)
  • Clear cell sarcoma of the kidney (CCSK)
  • Malignant rhabdoid tumour of the kidney (MRTK)
  • Clear cell renal cell carcinoma (ccRCC)
  • Papilliary renal cell carcinoma (pRCC), subtypes type 1 and type 2
  • Chromophobe renal cell carcinoma (ChRCC), subtype "Metabolically divergent ChRCC"


Matthew D. Young, Thomas D. Mitchell and Lars Custers et al. (2021). Single cell derived mRNA signals across human kidney tumors. Nature Communications. DOI:


This work was funded by Wellcome, the St. Baldrick's Foundation, Great Ormond Street Hospital Children's Charity (J.C.A.), Children Cancer-free Foundation (KiKa), and Great Ormond Street Hospital Biomedical Research Centre.

Selected websites:

About the Princess Máxima Center

Every year some 600 children in the Netherlands are diagnosed with cancer. One in four children with cancer still dies from the disease.

In order to cure children from cancer, all care and research in the Netherlands is concentrated in the Princess Máxima Center for Pediatric Oncology in Utrecht. More than ten years ago, parents and healthcare professionals took the initiative. The new pediatric oncology center was opened by Queen Máxima of the Netherlands on 5 June 2018.

The mission of the Princess Máxima Center is to cure every child with cancer, with optimal quality of life. The Princess Máxima Center is the largest pediatric oncology center in Europe where care and research are closely intertwined. Approximately 400 scientists and more than 800 healthcare professionals work closely together. Find out more at

About Research at Great Ormond Street Hospital

Great Ormond Street Hospital is one of the world's leading children's hospitals with the broadest range of dedicated, children's healthcare specialists under one roof in the UK. The hospital's pioneering research and treatment gives hope to children from across the UK with the rarest, most complex and often life-threatening conditions. All research at Great Ormond Street Hospital NHS Foundation Trust and UCL Great Ormond Street Institute of Child Health is made possible by the NIHR Great Ormond Street Hospital Biomedical Research Centre.

The Wellcome Sanger Institute

The Wellcome Sanger Institute is a world leading genomics research centre. We undertake large-scale research that forms the foundations of knowledge in biology and medicine. We are open and collaborative; our data, results, tools and technologies are shared across the globe to advance science. Our ambition is vast - we take on projects that are not possible anywhere else. We use the power of genome sequencing to understand and harness the information in DNA. Funded by Wellcome, we have the freedom and support to push the boundaries of genomics. Our findings are used to improve health and to understand life on Earth. Find out more at or follow us on Twitter, Facebook, LinkedIn and on our Blog.

About Wellcome

Wellcome supports science to solve the urgent health challenges facing everyone. We support discovery research into life, health and wellbeing, and we're taking on three worldwide health challenges: mental health, global heating and infectious diseases.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.